Patients who received immunotherapy regimens could continue to receive treatment beyond disease progression if they met prespecified criteria, as described in the Methods section in the Supplementary Appendix. Nebenwirkungen können unter Nivolumab oder Nivolumab in Kombination mit Ipilimumab jederzeit während oder nach der Behandlung auftreten. Panel A shows the primary end point of overall survival in patients in whom 1% or more of tumor cells expressed PD-L1 (programmed death ligand 1) in the group that received nivolumab plus ipilimumab and in the group that received chemotherapy. Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.e15134 Background: We use a decision analytic model to project the effectiveness and cost burden of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic … In the primary analysis from this trial, the median duration of overall survival was significantly longer with nivolumab plus ipilimumab than with chemotherapy among patients with advanced NSCLC who had a PD-L1 expression level of 1% or more. Analyses of all other end points were also descriptive. This report is based on the final analysis of overall survival with nivolumab plus ipilimumab, as compared with chemotherapy, in patients with a PD-L1 expression level of 1% or more, as of the database lock of July 2, 2019. We used a nonparametric log-rank test to assess the primary and secondary hierarchical end points and a stratified Cox proportional-hazards model, with the treatment group as a single covariate, to calculate hazard ratios for death with associated two-sided confidence intervals (which were 97.72% confidence intervals for end points tested in the statistical hierarchy). Nivolumab in combination with ipilimumab is a potential cost-effective treatment option for patients with intermediate or poor risk renal cell carcinoma (RCC), according to a study presented at the virtual 2020 ESMO Annual Congress. Tecentriq (atezolizumab) prescribing information. Data regarding treatment duration, number of doses, and subsequent therapies within PD-L1 subgroups and in all patients are provided in Tables S6, S7, and S8. Valuable tools for building a rewarding career in health care. Zur Anwendung von Nivolumab bei Schwangeren liegen keine Daten vor und das potentielle Risiko für den sich entwickelnden Fötus ist nicht bekannt. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.). Nivolumab has been approved in patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. Moreover, a substantial fraction of The most trusted, influential source of new medical knowledge and clinical best practices in the world. Among the 679 patients (58.2%) in whom the tumor mutational burden was evaluated, a similar degree of overall survival benefit was observed in patients who received nivolumab plus ipilimumab, regardless of whether they had a high tumor mutational burden or a low tumor mutational burden (≥10 vs. <10 mutations per megabase, respectively), despite the previous observation of improved progression-free survival in patients with a high tumor mutational burden.11. Keytruda (pembrolizumab) prescribing information. Cancer researchers are developing more effective ways to treat advanced melanoma, including using some drugs in combination. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. The median duration of overall survival and rates of overall survival at 1 year and 2 years with nivolumab plus ipilimumab were nearly identical in these two PD-L1 subgroups. Dr. Matthew D. Hellman vom Memorial Sloan Kettering Cancer Center in New York City und Kollegen randomisierten Patienten mit Stadium IV oder … (nivolumab, pembrolizumab) as single agents or combined with ipilimumab. In this subgroup, 3 treatment-related deaths occurred in the group that received nivolumab plus ipilimumab and 4 in the group that received nivolumab plus chemotherapy. Duale Blockade von PD-1 und CTLA-4-vermittelten Signalwegen führte in genidentischen Maus­modellen zu synergistischer Tumoraktivität. Gegenanzeigen sind Überempfindlichkeit gegen den Wirkstoff  Nivolumab oder einen der sonstigen Bestandteile der Arzneizubereitung. The most common treatment-related select adverse events of any grade with a potential immunologic cause in the group that received nivolumab plus ipilimumab were skin reactions (in 34.0% of the patients) and endocrine events (in 23.8%) (Table S10). Larkin J, Chiarion-Sileni V, Gonzalez R, et al. ); Limoges University Hospital, Limoges (A.V. CNS denotes central nervous system. Supported by Bristol-Myers Squibb and Ono Pharmaceutical. Ungefähr einheitliche Talspiegel im Steady-State wurden bei einer an das Körpergewicht angepassten Dosierung erzielt. Find What Is A Dove and Related Articles. Beim metastasierten Melanom kann die Kombination einer Nivolumab (anti-PD-1) und Ipilimumab (anti-CTLA-4) – vermittelten Hemmung eine verbesserte Anti-Tumor-Aktivität bewirken. Der Hersteller informiert. Steve Cimino Nivolumab plus ipilimumab was deemed cost effective compared with sunitinib in advanced renal cell carcinoma (RCC), according to an analysis published in … From the Memorial Sloan Kettering Cancer Center, New York (M.D.H. The frequency of grade 3 or 4 adverse events that were determined by the investigator to be related to the trial treatment was similar in the group that received nivolumab plus ipilimumab and in the chemotherapy group (32.8% vs. 36.0%). The median duration of response was 23.2 months (95% CI, 15.2 to 32.2) with nivolumab plus ipilimumab and 15.5 months (95% CI, 12.7 to 23.5) with nivolumab monotherapy among the patients with a PD-L1 expression level of 1% or more; among those with a PD-L1 expression level of 50% or more, the median duration of response was 31.8 months (95% CI, 18.7 to not reached) and 17.5 months (95% CI, 13.5 to 31.0), respectively. 68,5% der eingeschlossenen Patienten hatten keine BRAF V600-Mutation. 28. † Nivolumab monotherapy was evaluated only in the primary-analysis population involving patients with a PD-L1 (programmed death ligand 1) tumor expression of 1% or more. Among the patients with a PD-L1 expression level of less than 1%, fewer grade 3 or 4 treatment-related adverse events or serious adverse events were reported with nivolumab plus ipilimumab (27.0% with adverse events and 16.2% with serious adverse events) than with nivolumab plus chemotherapy (55.8% and 19.2%, respectively). S3). The median duration of overall survival was 15.2 months (95% CI, 12.3 to 19.8) with nivolumab plus chemotherapy and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy alone. Rizvi NA, Cho BC, Reinmuth N, et al. If a hierarchical end point was not met, the remaining end points in the hierarchy were considered to be descriptive only. Here, we compared the efficacy and cost … . Before we initiated this trial, some24-27 but not all28 studies had shown that survival was not affected by tumor mutational burden with chemotherapy treatment. There is the potential for improved responses with the use of combination immunotherapy. The 2-year overall survival rates were 40.4% for nivolumab plus ipilimumab and 23.0% for chemotherapy. Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P=0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. Über 110.000 Arzneimittel und Medizinprodukte mit Anwendungs- und Fachinformationen. 2016 (https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150027c.pdf). Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. Subsequent therapy was determined at the physician’s discretion. Foundation Medicine. Among all the trial patients, regardless of the PD-L1 expression level, the median duration and rate of overall survival were higher among the patients who received nivolumab plus ipilimumab than among those who received chemotherapy, with a duration of 17.1 months (95% CI, 15.2 to 19.9) and 13.9 months (95% CI, 12.2 to 15.1), respectively, and a rate of overall survival of 40.1% and 29.7%, respectively, at 2 years (Figure 2B); the overall survival benefit was consistent across most subgroups (Fig. N Engl J Med 2018;378:2093-2104. Conclusions: Nivolumab plus ipilimumab as first-line treatment could gain more health benefits for advanced RCC in comparison with standard sunitinib, which is considered to be cost-effective in the US and China but not in the UK. Initial marketing-authorisation documents. J Clin Oncol 2019;37:992-1000. Sie schloss nur Patienten ohne BRAF V600-Mutation … Prices start at $12,990.29 Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Shown is the risk of death among the patients who received nivolumab plus ipilimumab and in those who received chemotherapy according to the tumor PD-L1 expression level, tumor mutational (mut) burden, or both in prespecified randomized groups or in exploratory groups. This retrospective study included 1,474 patients who received nivolumab with or without ipilimumab. 2. Michael Atkins, MD Long-term follow-up results from CA209-004, a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab (Opdivo) plus ipilimumab (Yervoy), showed favorable survival Dako. Outcomes. 26. 5. In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). 16. Fundamental mechanisms of immune checkpoint blockade therapy. S6 and S7 and Table S9). Key exclusion criteria were the presence of EGFR mutations or known ALK translocations sensitive to targeted therapy, autoimmune disease, or untreated or symptomatic central nervous system metastases. Der PD1-Rezeptor ist als negativer Regulator der T-Zellaktivität an der Kontrolle der T-Zellreaktionen beteiligt. Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC). First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. Die Anwendung von Nivolumab in der Schwangerschaft wird nicht empfohlen, es sei denn, der klinische Nutzen überwiegt das potentielle Risiko. Trial-group assignments are summarized in Figure S2 and Table S3. Compare prices, print coupons and get savings tips for Nivolumab (Opdivo) and other Melanoma drugs at CVS, Walgreens, and other pharmacies. The comparators were observation, low-dose interferon and pembrolizumab. The overall survival rate at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, compared with 26% in the ipilimumab group. In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Tabelle 2: Empfohlene Dosis und Infusionszeit für die intravenöse Verabreichung von Nivolumab in Kombination mit Ipilimumab für Melanom Kombinationsphase, alle 3 Wochen für 4 Dosierungszyklen Monotherapiephase Nivolumab 1 mg/kg über 30 Minuten 240 mg alle … Nach Beginn der Nivolumab-Therapie können systemische Kortikosteroide oder andere Immunsuppressiva jedoch eingesetzt werden, um immunvermittelte Nebenwirkungen zu behandeln. Über 10.000 Inhaltsstoffe mit Wirkstoff-Informationen und Präparate-Zuordnung. At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab … Ready N, Hellmann MD, Awad MM, et al. Treatment-related deaths occurred in 8 patients who received nivolumab plus ipilimumab and in 6 patients who received chemotherapy (Table 2). In the phase I trial of nivolumab + ipilimumab, an asymptomatic increase in lipase was the primary DLT that informed the RP2D. DOI: 10.1056/NEJMoa1910231, Tap into groundbreaking research and clinically relevant insights. ); the Saitama Cancer Center, Saitama, Japan (H.S. Combining nivolumab with ipilimumab has proved to be effective in melanoma and renal-cell carcinoma in previous studies,8,9,22 yet a key question before this trial was whether the addition of CTLA-4 inhibition to PD-1 blockade contributes to benefit in patients with NSCLC. Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. Bitte melden Sie sich an, um vollen kostenlosen Zugriff auf alle Fachinformationen zu erhalten. In patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P=0.007) (Figure 1A). Crossover between the treatment groups during the trial was not permitted. S9 and Table S9). Part 1 of the trial has two independent primary end points. 21. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. From August 2015 through November 2016, a total of 2876 patients were enrolled in CheckMate 227 Part 1; of these patients, 1739 underwent randomization. Nivolumab ist bei erwachsenen Patienten zur Behandlung folgender Tumorarten indiziert: Nivolumab ist ein humaner Immunoglobulin-G4-(IgG4) monoklonaler Antikörper, der an den Programmierten Zelltod 1-(PD-1)-Rezeptor bindet und die Interaktion des Rezeptors mit seinen  Liganden PD-L1 und PD-L2 verhindert. Lancet 2019;393:1819-1830. Zum Vergleich von Nivolumab versus Ipilimumab bei Patienten mit BRAF V600-Mutation ist die Studie CA209-067 geeignet. r The phase II CheckMate 069 study showed similar efficacy and toxicity for patients receiving combination ipilumumab/nivolumab and ipilimumab monotherapy respectively. Das progressionsfreie Überleben (PFS) nahm von 2,9 Monaten unter Ipilimumab auf 6,9 Monate unter Nivolumab und auf 11,5 Monate unter Nivolumab plus Ipilimumab zu. Nivolumab (Opdivo®) + Ipilimumab (Yervoy®) Immunotherapy for advanced melanoma activates your immune system to attack the cancer cells. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services. r An ECOG score of 2 or more was reported in 4 patients in the group with PD-L1 expression of 1% or more and in 6 patients in the overall population; data were missing for 3 patients and 2 patients in the two populations, respectively. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Table 2. The minimum follow-up for overall survival was 29.3 months. The stratified hazard ratio for the overall population is shown with a 97.72% confidence interval (CI). Cancer Cell 2019;35(2):238.e6-255.e6. Kowanetz M, Zou W, Shames DS, et al. The unexpected effect of the tumor mutational burden on the overall survival of patients who received chemotherapy may have contributed to these results. Durch ein malignes Melanom entstandene Metastasen werden bei mir (nach 10 x Kopfbestrahlung) seit Kurzem mit Nivolumab/Ipilimumab behandelt. Die Mehrheit der Nebenwirkungen war leicht bis mäßig. Opdivo (nivolumab) is a member of the anti-PD-1 monoclonal antibodies drug class and is commonly used for Colorectal Cancer, Esophageal Carcinoma, Head and Neck Cancer, and others. Benefits for nivolumab plus ipilimumab with respect to progression-free survival, objective response rate, and duration of response were also seen in patients with a PD-L1 expression level of less than 1% and in all the trial patients (Figs. Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a … Nat Genet 2019;51:202-206. Ipilimumab schwächt dagegen die Hemmwirkung des Moleküls CTLA-4 … Prices start at $12,990.29 If the proportional assumption was not met, hazard ratios were still reported to provide a conventional estimate of overall average effect and supplemented by median and landmark estimates. The characteristics of the patients were balanced across the treatment groups at baseline (Table 1 and Tables S4 and S5). Behandlungsbedingte unerwünschte Ereignisse, die zum Abbruch führten, traten bei 22% … The hazard ratio for death of 0.79 (97.72% confidence interval, 0.65 to 0.96) (Table S2) provides an overall estimate of benefit and should be interpreted in the context of the shape of the curves, which are characterized by transient initial survival benefit with chemotherapy, followed by long-term benefit with nivolumab plus ipilimumab. Information, resources, and support needed to approach rotations - and life as a resident. Die Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. Table 1. Among the patients with a PD-L1 expression level of less than 1%, the rate of progression-free survival was significantly higher with nivolumab plus chemotherapy than with chemotherapy alone (10.5% vs. 4.6% at 2 years; hazard ratio for disease progression or death, 0.73; 97.72% CI, 0.56 to 0.95; P=0.007). Key Points Question Is pembrolizumab-axitinib cost-effective as first-line treatment of advanced renal cell carcinoma compared with nivolumab-ipilimumab, the other preferred first-line regimen? Nivolumab ist als monoklonaler Antikörper ein Eiweißstoff. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. § The status of PD-L1 expression was determined with the use of the PD-L1 IHC 28–8 pharmDx assay (Dako). Ovvero che il 54% dei pazienti ha avuto gravi ripercussioni collaterali del tipo “pausa ad effetto” , ha detto Suzanne Topalian, direttore del programma melanoma presso la Johns Hopkins Kimmel Cancer Center di Baltimora e ricercatore leader nell’immunoterapia. Also shown are the 1-year and 2-year rates of survival in the two groups. The tube stays in place throughout the course of treatment. Nivolumab bindet an den Rezeptor PD-1 auf T-Lymphozyten und verhindert so dessen abwehrhemmende Wirkung. 9. S8). On the performance-status evaluation of the Eastern Cooperative Oncology Group (ECOG), a score of 0 indicates that the patient is fully active, and a score of 1 indicates that the patient is restricted in physically strenuous activity but ambulatory. N Engl J Med 2018;379:2040-2051. Overall survival rates at 1 year and 2 years were 62.6% and 40.0%, respectively, with nivolumab plus ipilimumab, as compared with 56.2% and 32.8%, respectively, with chemotherapy. N Engl J Med 2016;375:1823-1833. Gelbe Liste Online ist ein Online-Dienst der At 2 years, the overall survival rate was 40.4% and 34.7%, respectively. These treatments include monotherapy blockade of programmed death 1 (PD-1) in patients with tumors that express programmed death ligand 1 (PD-L1) or such treatment in combination with chemotherapy, regardless of tumor PD-L1 expression.1-7 Still, current therapies extend long-term survival in only a minority of patients with NSCLC. 16.11.2020 - Bei OPDIVO 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung haben sich die Indikationen erweitert. PD-L1 IHC 28-8 pharmDx. Toxicity and response criteria of the Eastern Cooperative Oncology Group. 15. Daher muss unter Abwägung des Nutzens des Stillens für das Kind und des Nutzens der Behandlung für die Mutter eine Entscheidung darüber getroffen werden, ob das Stillen oder die Behandlung mit Nivolumab unterbrochen werden soll. Ipilimumab was estimated to cost the most per patient, driven by the cost of the drug. Characteristics of the Patients at Baseline.*. All treatment-related adverse events and serious adverse events were reported during the time between the first dose of a trial treatment and 30 days after the last dose. Prespecified analyses that were not part of the statistical testing hierarchy are descriptive (Table S1). In Part 1b, patients were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab (360 mg every 3 weeks) plus platinum-doublet chemotherapy (every 3 weeks for up to four cycles), or platinum-doublet chemotherapy alone (every 3 weeks for up to four cycles). (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; … Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer N Engl J Med. Nebenwirkungen bislang: Ich habe seit 5 Tagen heftigen Durchfall, bin sehr müde und antriebslos, natürlich auch geschwächt. Costo del sovrappeso in pazienti in terapia con ipilimumab per melanoma avanzato in tre centri oncologici italiani NICOLETTA JANNITTI U.O.C. Among the patients who had disease progression during the trial, subsequent systemic therapy was administered in 43.6% of the patients who had received nivolumab plus ipilimumab and in 55.8% of those who had received chemotherapy; immunotherapy was administered in 42.4% of those in the chemotherapy group. Deshalb ist nicht zu erwarten, dass gleichzeitig verabreichte Arzneimittel die Pharmakokinetik von Nivolumab durch Hemmung oder Induktion dieser Enzyme verändert. 4. Chicago – Eine Erstlinientherapie mit Nivolumab in Monotherapie oder in Kombination mit Ipilimumab ist bei Patienten mit metastasiertem Melanom signifikant wirksamer als eine Monotherapie mit Ipilimumab. Mok TSK, Wu YL, Kudaba I, et al. Nivolumab alleine oder in Kombination mit Ipilimumab ist mit immunvermittelten Nebenwirkungen assoziiert. Shown is the median duration of overall survival in patients in the group that received nivolumab plus ipilimumab and in the group that received chemotherapy among those who had a tumor PD-L1 expression level of less than 1% (Panel A) and among those in the overall population (Panel B). Ipilimumab schwächt dagegen die Hemmwirkung des Moleküls CTLA-4 auf den T-Lymphozyten. Nivolumab bindet an den Rezeptor PD-1 auf T-Lymphozyten und verhindert so dessen abwehrhemmende Wirkung. We planned to enroll 1200 patients for randomization into the three treatment groups in Part 1a. PATIENTS AND METHODS We conducted a phase II study of nivolumab with ipilimumab in patients with … Deshalb sollten Patienten mindestens bis 5 Monate nach der letzten Dosis engmaschig überwacht werden. Nivolumab and ipilimumab were administered intravenously at 1 mg/kg over 30 minutes and 3 mg/kg over 30 minutes, respectively, every 3 weeks for up to four doses, followed by 480 mg nivolumab every 4 weeks until disease progression or unacceptable toxicity. Schwere Nebenwirkungen (Grad 3 oder 4) traten bei 250 Patienten (46%) bzw. Ipilimumab was no longer dominated by nivolumab when the total drug cost of ipilimumab (4 doses) decreased to approximately $88,000. 11. Im Dosisbereich von 0,1 bis 10 mg/kg ist die Pharmakokinetik von Nivolumab linear. Details regarding tissue requirements for PD-L1 screening and chemotherapy regimens are provided in the Methods section in the Supplementary Appendix. Treatment-Related Adverse Events in All the Recipients of Nivolumab plus Ipilimumab or Chemotherapy.*. An overall survival benefit with nivolumab plus ipilimumab, as compared with chemotherapy, was observed regardless of the subgroup of PD-L1 expression level. 27. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. However, nivolumab remained cost-effective compared with ipilimumab with an ICER of $59 per PFQALY, while combination therapy had an ICER of $114,858 per PFQALY compared with nivolumab monotherapy ( Table 3 ). Genome Med 2017;9:34-34. Adverse events leading to the discontinuation of ipilimumab earlier than the discontinuation of nivolumab occurred in 18 patients (3.1%). Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients. At 2 years, the rate of ongoing response was 49% with nivolumab plus ipilimumab, as compared with 11% with chemotherapy. The study randomised 945 treatment-naive patients with stage III or IV melanoma; 314 patients received nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg every 3 weeks for 4 doses followed by nivolumab at 3 mg/kg every 2 weeks, 316 patients received nivolumab at 3 mg/kg every 2 weeks plus ipilimumab-matched placebo, and 315 patients received ipilimumab at 3 mg/kg every 3 weeks for 4 … Zum Vergleich von Nivolumab versus Dacarbazin ist die Studie CA209-066 geeignet.